Lucicapiva (capivasertib) 160 mg is a targeted therapy medication used in combination with fulvestrant for the treatment of advanced or metastatic breast cancer in adults
LuciCapiva is a kinase inhibitor indicated, in combination with Fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer
